Combined drug-radiation treatment: biological basis, current applications and perspectives
The course is aimed at radiation oncologists and medical oncologists involved in the multidisciplinary treatment of cancer.
Barbara Jereczek-Fossa, Radiation Oncologist and Clinical Oncologist, European Institute of Oncology and University of Milan, Milan (IT)
Christophe Hennequin, Radiation Oncologist, Hospital Saint-Louis, Paris (FR)
Giuseppe Curigliano, Medical Oncologist, European Institute of Oncology, Milan (IT)
Jesper Grau Eriksen, Clinical Oncologist, Odense University Hospital, Odense (DK)
Li Tee Tan, Consultant Oncologist, Cambridge University Hospital, NHS Trust, Cambridge (UK)
Martin Pruschy, Biologist, University Hospital Zürich, Zürich (CH)
Umberto Ricardi, Radiation Oncologist, University of Turin, Turin (IT)
Robert Glynne-Jones, Clinical Oncologist, Mount Vernon Cancer Centre, Northwood (UK)
COURSE AIM/RATIONALECourse rationale
Effective cancer treatment necessitates both high efficacy of local treatment and combatting sub-clinical systemic disease. Consequently, cancer therapy today involves various combinations of local and systemic treatment modalities. Of those, combining drugs and radiation has been attracting particular attention both in terms of its biological rationale and its potential of increasing the therapeutic outcome. The course aims at updating participants about established and emerging knowledge in this field. It will provide the key-messages that biological and clinical research is currently bringing to the oncology community.
This course aims to:
- Update participants about biological effects of combining drugs and radiation in normal and tumour tissue
- Present evidence-based clinical applications of combined modality treatment using drugs and radiation in major human malignancies
- Stimulate case-based discussion on the interdisciplinary treatment of cancer
- Present future perspectives for combining drugs and radiation.